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Response to the letter by Ooi et al.Dear Sir,
We read with interest the letter from Dr. CY Ooi and Coll.[1]
pointing out that more clinical and experimental evidence is
needed before firm recommendations concerning long-term use
of UDCA in CFLD are issued.
We agree that achieving substantial improvement, and even
normalization, of liver biochemistries in CFLD patients while
on UDCA treatment does not necessarily mean that administra-
tion of this bile acid is effective on clinical grounds. We also
agree that there are few randomized trials that have addressed
the potential efficacy and safety of UDCA in CFLD [2,3]. We
have for many years discussed the need for prospective
double-blind studies of UDCA treatment in patients with CF,
but it has been difficult to get acceptance for these studies to
date. On the other hand, evidence has been provided of stabili-
zation in progression of CFLD while on UDCA, using liver bi-
opsy, ultrasound and clinical symptoms as the outcome [4–7].
With regard to the dose, a dose–response study has clearly
shown that in CF patients a biliary enrichment with UDCA
comparable to that achieved in adults with both normal and ab-
normal hepatic function was only obtained at the dose of
20 mg/kg/day, that was also associated with greater biochemi-
cal improvement [8].
The concern expressed by Ooi et al. [1] about the use of
UDCA in the treatment of patients with suspected CFLD is
mainly based on the study of Lindor et al. [9] on its use in Prima-
ry Sclerosis Cholangitis (PSC), and on the fact that UDCA was
not effective in very severe CFLD. Currently, it is not known
why 2–5% of patients with CF develop severe liver disease
and therefore it is not possible to identify those patients who
would benefit. Practical experience and a single center study
(published in abstract form) [10] indicate that UDCA is more
beneficial when it is started before the onset of severe disease.
It is not pertinent to compare CFLD with PSC as the diseases
are different in etiology, pathology, degree of cholestasis and
prognosis [11–13]. Furthermore, as pointed out by Lindor et
al. [6], the authors used much higher doses than given in earlier
studies in PSC with favorable results. It is well known that
UDCA can be epimerized to chenodeoxycholic acid and also
transformed by the bacterial flora to lithocholic acid [14],
which both are liver toxic. It is likely that higher doses increase
the risk of such transformation and as Lindor et al. did not inves-
tigate the bile acid pattern during long-term treatment, it cannot
be excluded that this contributed to their negative results.1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.09.003At present UDCA has been in clinical use since more than
two decades and to the best of our knowledge no studies have
shown clinically relevant adverse outcomes nor any unfavor-
able effects on liver disease progression that could be related
to UDCA or to the doses recommended for CF patients.
We thank Dr. CY Ooi and Coll. for their comments, and ap-
preciate their cautious approach suggesting a watchful eye to be
always kept on CF patients undergoing UDCA treatment. Should
sound data from any authors involved in CF patients' manage-
ment provide evidence of unfavorable effects to UDCA adminis-
tration in long-term clinical studies or well documented clinical
case reports, the present guidelines are ready for being promptly
modified.
For our part, using mass spectrometry with stable-isotope di-
lution analysis, some of us are presently addressing the issue of
possible UDCA toxicity in a clinical study exploring the meta-
bolic fate of this bile acid in CF patients.
Meanwhile, we deem there are no compelling arguments for
precluding CF patients to start UDCA early, before the liver
disease has potentially progressed to a stage at which changing
its course by any medical treatment is no longer possible.References
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